The US Supreme Court unanimously affirmed an appeals court ruling that Amgen, Inc.’s patents claiming to cover all antibodies that bind to the PCSK9 protein are invalid. The decision is a relief for many in the biopharma sector who were concerned that a finding for Amgen could deter innovation.
Amgen alleged that Sanofi and Regeneron Pharmaceuticals, Inc.’s anti-PCSK9 antibody Praluent (alirocumab) infringes two patents that cover a...